protein

SNAP25,1-206aa, Human, E Coli

MBS203168

0.1 mg

310 USD

Recombinant Protein

SNAP25,1-206aa, Human, E Coli

[SNAP25]

[Synaptosomal-associated protein 25 isoform SNAP25B; FLJ23079; SNAP25; RIC-4; RIC4; SEC9; SNAP; SNAP-25; Synaptosomal-associated protein 25 isoform SNAP25B; Synaptosomal-associated protein 25 isoform SNAP25B SuP; Super protein; bA416N4.2; Bdr; dJ1068F16.2; HGNC:11132; MGC105414; MGC139754; Resistance to inhibitors of cholinesterase 4 homolog; RIC 4; SEC9; SNAP 25; SNAP-25B; SNP 25; SNP25; sp; Synaptosomal associated 25 kDa protein; Synaptosomal associated protein; Synaptosomal associated protein 25; Synaptosomal associated protein 25kDa.]

[synaptosomal-associated protein 25 isoform SNAP25B; Synaptosomal-associated protein 25; synaptosomal-associated protein 25; synaptosome associated protein 25; Super protein; SUP; Synaptosomal-associated 25 kDa protein]

[SNAP25]

[SNAP25; SNAP25; SUP; RIC4; SEC9; SNAP; CMS18; RIC-4; SNAP-25; bA416N4.2; dJ1068F16.2; SNAP; SNAP-25; SUP]

E Coli

206

> 90% by SDS-PAGE

Liquid in 25mM Tris pH 7.5, 1mM DTT, 10% glycerol

1 mg/ml (determined by Bradford assay)

Can be stored at 4°C short term (1 week). For long term storage, aliquot and store at -20°C or -80°C. Avoid repeated freezing and thawing cycles.

SDS-PAGE

SDS-Page

Tag: Non-Tagged

Neuroscience

The synaptosomal-associated protein (SNAP-25) is an essential component of the core complex that mediates presynaptic vesicle trafficking. Thus, SNAP-25 is directly involved in the release of neurotransmitters and this protein exists as two alternative isoforms, SNAP25A and SNAP25B which differ by 9 amino acids in central portion of these proteins. Recombinant SNAP25B protein was expressed in E Coli and purified by using conventional chromatography techniques.

Tafoya LC., et al. (2006) J. Neurosci. 26 (30):7826-38.; Schulz JR., et al. (1998) J. Biol Chem. 273 (38):24355-9.;

18765735

NP_570824

NM_130811.3

P60880

23 kDa (206 aa), confirmed by MALDI-TOF.

Acetylcholine Neurotransmitter Release Cycle Pathway (1268773); Disease Pathway (1268854); Dopamine Neurotransmitter Release Cycle Pathway (1268772); Effects Of Botulinum Toxin Pathway (138028); GABA Synthesis, Release, Reuptake And Degradation Pathway (1268774); Glutamate Neurotransmitter Release Cycle Pathway (1268771); Immune System Pathway (1269170); Infectious Disease Pathway (1269056); Innate Immune System Pathway (1269203); Insulin Signaling Pathway (198845)

Synaptic vesicle membrane docking and fusion is mediated by SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors) located on the vesicle membrane (v-SNAREs) and the target membrane (t-SNAREs). The assembled v-SNARE/t-SNARE complex consists of a bundle of four helices, one of which is supplied by v-SNARE and the other three by t-SNARE. For t-SNAREs on the plasma membrane, the protein syntaxin supplies one helix and the protein encoded by this gene contributes the other two. Therefore, this gene product is a presynaptic plasma membrane protein involved in the regulation of neurotransmitter release. Two alternative transcript variants encoding different protein isoforms have been described for this gene. [provided by RefSeq, Jul 2008]

t-SNARE involved in the molecular regulation of neurotransmitter release. May play an important role in the synaptic function of specific neuronal systems. Associates with proteins involved in vesicle docking and membrane fusion. Regulates plasma membrane recycling through its interaction with CENPF. Modulates the gating characteristics of the delayed rectifier voltage-dependent potassium channel KCNB1 in pancreatic beta cells.

0.1 mg

310 USD

0.5 mg

720